Literature DB >> 7249543

Airway and metabolic responsiveness to intravenous salbutamol in asthma: effect of regular inhaled salbutamol.

J E Harvey, C J Baldwin, P J Wood, K G Alberti, A E Tattersfield.   

Abstract

1. Airway, metabolic and cyclic nucleotide responses to intravenous salbutamol were measured in five patients with mild asthma who had taken no medication in the week before the study. The studies were repeated after the patient had taken regular inhaled salbutamol for 4 weeks, in doses increasing to 2000 micrograms daily in week 4. 2. The pretreatment airway, metabolic and cyclic nucleotide responses to salbutamol were similar to those previously reported in normal subjects. These patients therefore did not show evidence of partial beta-adrenoceptor blockade. 3. After 4 weeks' salbutamol therapy the airway response to intravenous salbutamol was unchanged. 4. The glucose, pyruvate and adenosine 3':5'-cyclic monophosphate (cyclic AMP) responses to intravenous salbutamol were depressed after regular salbutamol administration. The dose-response curve for non-esterified fatty acids and insulin, though displaced downwards, did not indicate an impaired response to salbutamol since the shape was unchanged. There was no significant change in the lactate, glycerol and total ketone response. 5. This study confirms that tissues differ in the ease with which they develop resistance to beta-adrenoceptor agonists. Asthmatic airways appear to be relatively protected from developing assistance when compared with other tissues in asthmatic patients and when compared with the airways of normal subjects.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249543     DOI: 10.1042/cs0600579

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  20 in total

1.  Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.

Authors:  K Larsson; P Hjemdahl
Journal:  Thorax       Date:  1989-09       Impact factor: 9.139

Review 2.  Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  R N Brogden; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol.

Authors:  B J Lipworth; R A Clark; D P Dhillon; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Beta-adrenoceptor responses to inhaled salbutamol in normal subjects.

Authors:  B J Lipworth; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Alveolitis associated with sulphamethoxypyridazine.

Authors:  J C Porter; J S Friedland; F Wojnarowska; J G Ledingham
Journal:  Thorax       Date:  1989-09       Impact factor: 9.139

6.  Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.

Authors:  S R Smith; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

7.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

Authors:  P J Barnes; N B Pride
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

8.  Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?

Authors:  J G Maconochie; N A Minton; J E Chilton; O N Keene
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

Review 9.  Beta 2 adrenergic receptors in asthma: a current perspective.

Authors:  T R Bai
Journal:  Lung       Date:  1992       Impact factor: 2.584

10.  Regular nebulised terbutaline in chronic obstructive airways disease: dose-response studies fail to detect tolerance.

Authors:  C Teale; S B Pearson
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.